申请人:Farmitalia Carlo Erba S.p.A
公开号:US04490376A1
公开(公告)日:1984-12-25
Compounds of the formula (I) ##STR1## wherein R.sub.1 is: (a) hydrogen, or C.sub.1 -C.sub.6 alkyl; (b) an unsubstituted 2-pyridyl or 3-pyridyl group; (c) a benzyl group, wherein the phenyl ring is unsubstituted or substituted by halogen, C.sub.1 -C.sub.6 alkoxy or C.sub.1 -C.sub.6 alkyl; (d) a phenyl ring, unsubstituted or substituted by one or two groups chosen from halogen, trihalomethyl, C.sub.1 -C.sub.6 alkoxy, C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkanoylamino, nitro and amino; each of R.sub.2 and R.sub.3 independently represents hydrogen, halogen or C.sub.1 -C.sub.6 alkyl; R.sub.4 represents a 2-pyridyl, 3-pyridyl or 4-pyridyl group, unsubstituted or substituted by C.sub.1 -C.sub.6 alkyl; and the pharmaceutically acceptable salts thereof are disclosed. The compounds have activity in the gastroenteric system, particularly anti-ulcerogenic and gastric anti-secretory activity. Additionally, the compounds have activity in reducing the undesired gastrointestinal side-effects resulting from systemic administration of anti-inflammatory prostaglandin synthetase inhibitors.
化合物的化学式为(I) ##STR1## 其中R.sub.1是:(a) 氢,或C.sub.1-C.sub.6烷基;(b) 未取代的2-吡啶基或3-吡啶基;(c) 苄基,其中苯环未取代或被卤素、C.sub.1-C.sub.6烷氧基或C.sub.1-C.sub.6烷基取代;(d) 苯环,未取代或被卤素、三卤甲基、C.sub.1-C.sub.6烷氧基、C.sub.1-C.sub.6烷基、C.sub.2-C.sub.6烷酰胺基、硝基或氨基中的一种或两种基团取代;R.sub.2和R.sub.3各自独立地表示氢、卤素或C.sub.1-C.sub.6烷基;R.sub.4表示2-吡啶基、3-吡啶基或4-吡啶基,未取代或被C.sub.1-C.sub.6烷基取代;以及其药学上可接受的盐。这些化合物在胃肠系统中具有活性,特别是抗溃疡和胃抑酸活性。此外,这些化合物在减少系统给药的抗炎前列腺素合酶抑制剂引起的不良胃肠副作用方面也具有活性。